• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: MDXXF )

    0.2045 +0.0070 (+3.54%)
    Streaming Delayed Price Updated: 12:11 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about MDXXF

    PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Launches MDMA Clinical Trial Tool for Researchers
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
    From PharmAla Biotech
    Via GlobeNewswire
    Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
    Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
    From PharmAla Biotech
    Via GlobeNewswire
    Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
    Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
    From PharmAla Biotech
    Via GlobeNewswire
    Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
    Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications 
    From PharmAla Biotech
    Via GlobeNewswire
    Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
    PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market 
    From PharmAla Biotech
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.